Arcus Biosciences (RCUS) Misses Q1 EPS by 12c

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.14), $0.12 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $28 million versus the consensus estimate of $38.61 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Amylyx Pharmaceuticals (AMLX) 19K contracts trade
• Klarna Group (KLAR) 46K contracts trade, share price down 21.5%